Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.21−0.07 (-0.21%)
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Immunovant price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Immunovant's price to book ratio was 10.4× on Nov 11, 2026, against 8.1× a year earlier. Over the last 5 years it ranged from 1.0× to 22.0×, with a median of 6.9×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 10.4× | +1.9 |
| 2025 | Dec 31, 2025 | 8.5× | +0.5 |
| 2024 | Dec 31, 2024 | 8.1× | −13.9 |
| 2023 | Dec 29, 2023 | 22.0× | +16.8 |
| 2022 | Dec 30, 2022 | 5.2× | +3.4 |
| 2021 | Dec 31, 2021 | 1.8× | −8.5 |
| 2020 | Dec 31, 2020 | 10.3× | −41.2 |
| 2019 | Jul 31, 2019 | 51.5× | – |
See a number that looks wrong?